Free light chains (FLC) are the most commonly detected paraproteins in chronic lymphocytic leukemia (CLL). We examined the types of FLC abnormalities and prognostic utility of the FLC assay compared to standard prognostic biomarkers in a prospective cohort of 339 newly diagnosed CLL patients. Three types of FLC abnormalities were identified: monoclonal elevated FLC (elevated κ and/or λ with abnormal FLC ratio), polyclonal elevated FLC (elevated κ and/or λ with normal FLC ratio), and ratio-only FLC abnormality (normal range κ and λ with abnormal 
Introduction
A clonal lymphoid cell can differentiate to the point where it secretes paraproteins. This can occur in a variety of lymphoid conditions including multiple myeloma (MM), MGUS, and lymphoplasmacytic lymphoma (Waldenström's macroglobulinemia). Paraproteins are usually measured using assays that detect intact antibodies. However, assays are now available that can measure free light chains (FLC, kappa (κ), and lambda (λ)) in serum. 1 Quantitation of the serum free light chain paraprotein has been shown to have prognostic value in MGUS, 2 multiple myeloma (MM), 3 solitary plasmacytoma, 4 and light chain (AL) amyloidosis. 5 In addition to clonal FLC elevations, polyclonal increases in serum FLC have been identified in a number of patient populations with malignant and non-malignant diseases. These polyclonal increases in serum FLC are not associated with an abnormal FLC ratio and may be indicative of renal dysfunction, 6 older age, 7 autoimmune disease, 8 chronic inflammation, 9 or general immune stimulation.
FLC are also the most commonly detected paraproteins in chronic lymphocytic leukemia. 10-12 13 Our initial report on the prevalence of FLC abnormalities detected with the FLC assay in CLL samples from the Mayo Clinic Lymphoma SPORE serum bank reported a monoclonal protein in 44% of 18 CLL patients with 39% detected by FLC and 11% detected by PEL/IF. 14 Notably, in 6 of the 8 CLL patients with a paraprotein, the M-protein was only detectable by the FLC method.
Two subsequent retrospective studies including both treated and untreated patients reported abnormal FLC ratios in 30-40% of CLL patients. 15, 16 In both these series, patients with an abnormal FLC ratio had shorter time to treatment and overall survival, findings which persisted on multivariable analysis adjusting for immunoglobulin heavy chain variable region gene (IGHV) mutation status, B2M levels, and ZAP70 expression. 15 However, neither study used the FLC ratio to distinguish monoclonal vs. polyclonal elevations of FLC.
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The FLC assay is clinically available, simple, and relatively inexpensive and thus has the potential to be a valuable prognostic biomarker for patients with CLL. Here we report the first study on the prognostic implications of analysis of serum FLC in a prospectively enrolled cohort of newly diagnosed, untreated patients with CLL. The analysis is the first to examine prevalence and outcome association for both monoclonal and polyclonal FLC abnormalities and to perform comparative analysis assessing the prognostic value of the FLC assay relative to that of the other well-established prognostic biomarkers for CLL.
Material and Methods
Patients with CLL seen within nine months of diagnosis were prospectively enrolled in the University of Iowa / Mayo Clinic SPORE Molecular Epidemiology Resource (SPORE MER) from September 2002 through February 2008. Enrollment to the SPORE MER is offered to consecutive, newly diagnosed patients with CLL who were evaluated at Mayo Clinic Rochester or the University of Iowa within 9 months of diagnosis, were age 18 years and older, and were a US resident at diagnosis. The SPORE MER collects clinical, pathologic, demographic, and epidemiologic data along with blood and tumor samples from the patients at enrollment. Patients are systematically followed every six months for the first three years and then annually thereafter.
This study was reviewed and approved by the Human Subjects Institutional Review Board at the Mayo Clinic and the University of Iowa, and written informed consent was obtained from all participants in accordance with the Declaration of Helsinki. The clinical characteristics of this cohort have been previously reported. 17 All leukemia cell immunophenotype and pathology analyses were reviewed to confirm each case met the criteria for a diagnosis of CLL. All patients either had an absolute lymphocyte count (ALC) >5.0 x 10 9 /L and fulfilled the 1996 criteria for CLL 18 or fulfilled the WHO criteria for the small lymphocytic lymphoma variant of CLL.
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Baseline clinical, laboratory, and treatment data were abstracted from medical records using a standardized protocol. Prognostic testing (IGHV gene mutation analysis, ZAP-70 status, CD38 6 . All elevated FLC levels with normal κ:λ ratios were considered polyclonal. Patients with normal FLC levels but an abnormal κ:λ ratio were considered to have ratio-only FLC abnormalities.
Time to first treatment (TTFT) was defined as the time from diagnosis to disease progression requiring treatment. Overall survival was defined as time from diagnosis to death due to any cause. Patients without an event were censored at time of last known follow-up. Chisquared tests and Fisher's exact test, where appropriate, was used to assess association of FLC with clinical, prognostic, and demographic factors. Cox proportional hazards models and KaplanMeier curves were used to assess associations of FLC abnormalities with time-to-event outcomes.
Cox models were performed unadjusted as well as adjusted for Rai stage. The prognostic capability of biomarkers was assessed with time dependent ROC curves; 24 the area under the curve (AUC) with bootstrap confidence intervals used to assess the significance of differences.
Standard CLL biomarkers were assessed as used clinically or previously published for
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From prognostication. [20] [21] [22] 25 Lack of a sufficient number of events precluded multivariable modelling of FLC with the full set of other CLL prognostic markers. Thus, to explore the independent prognostic value of the FLC assay while accounting for known risk from these markers we created a 1 degree of freedom risk score to use as an adjustment variable in multivariable models.
The following risk factors were used as covariates: age, sex, Rai stage, CD38, ZAP-70, IGHV, CD49d, and FISH. The risk score was generated by the linear combination of the factor variables multiplied by their regression coefficients (ie, xβ) from Cox models for overall survival and time to first treatment. All statistical analyses were performed using SAS v9.1.3 and R v2.11.0.
Results
We studied 339 patients with newly diagnosed CLL who had pre-treatment serum collected for research purposes. Median age at diagnosis was 63 years (range: 37-91) and 67% of patients were 
FLC and tumor cell light chain restriction
In patients with both an elevated FLC and an abnormal FLC ratio (e.g. those with monoclonal 
Prognostic Utility of FLC relative to other prognostic biomarkers
Finally, time dependent receiver operating curves (ROC) curves were used to assess the 
Discussion
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From This is the first prospective study reporting the prognostic value of the FLC assay in a cohort of newly diagnosed CLL patients. Approximately half of CLL patients had FLC abnormalities and these abnormalities were strongly associated with clinical outcome. Notably, among those with FLC abnormalities, the type of abnormality determines its prognostic implications. Our study is the first to perform detailed assessment of the clinical implications of the various types of FLC abnormalities (e.g. clonal vs. polyclonal abnormalities) and to compare the prognostic value of the FLC assay, as measured by ROC analysis, to other CLL biomarkers. We show that serum FLC measurements compares favorably to other CLL prognostic biomarkers. This is an important finding because the FLC assay is a robust assay that is simple to perform, widely available, has a well established inter-laboratory reference range, 7 and is relatively inexpensive. Patients with polyclonal FLC elevations tended to be older, have higher PS, and elevated creatinine levels suggesting multiple possible etiologies for the FLC abnormality and indicating that this finding could be a marker of host "fitness". 26 Prevalence of high risk CLL biologic characteristics were similar to patients without FLC abnormalities, except for high risk FISH.
Cause of death in these patients was primarily due to non-CLL causes, again supporting an association of elevated polyclonal FLC with poor host fitness. However, because polyclonal FLC elevations were associated not only with shorter overall survival but also modestly associated with a shorter TTFT it is also possible that polyclonal FLC may nonetheless be a marker of poorer disease specific outcomes.
In patients with an abnormal FLC ratio and non-elevated levels (e.g. ratio only abnormalities), there was concordance of the predominant serum light chain and CLL light chain restriction in 92% of cases, suggesting that the abnormal FLC ratio was due to CLL cell light chain secretion. However, compared to patients with monoclonal elevated FLC, patients with ratio-only abnormalities were more similar to patients with normal FLC assay in terms of Rai
Stage and other prognostic factors. As a group, ratio-only FLC is associated with shorter TTFT.
Although overall survival is similar to patients with normal FLC in our study, this observation should be interpreted with caution until longer follow-up is available.
Strengths of our study include its prospective design, inclusion of only newly diagnosed patients all of whom provided prior to receiving any treatment, systematic follow-up, use of a single reference laboratory for FLC assays, and the ability to correlate the FLC measurements to multiple other CLL prognostic biomarkers. To the best of our knowledge, this study is also the largest to evaluate to prognostic importance of FLC in CLL and the first to assess how the type of FLC abnormality relates to outcome. The major limitation of this study is the relatively short follow up and limited number of events for a disease that has a relatively indolent course. For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
